Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

For patients with moderate-to-severe plaque psoriasis, ixekizumab is effective and safe, with induction therapy enhancing ...

Despite a $3.5 billion impairment charge from Emraclidine's failure, AbbVie's immunology portfolio, led by Skyrizi and Rinvoq ... being studied as a once-daily medicine for use as both a ...

Skyrizi, Ubrelvy, Vraylar, and Venclexta/Venclyxto. The company also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products, as well as botox ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...